Wenchun Chen 陈温纯1, Kayleigh M Voos1, Cassandra D Josephson1,2, Renhao Li1. 1. From the Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics (W.C., K.M.V., C.D.J., R.L.), Emory University School of Medicine, Atlanta, GA. 2. Department of Pathology (C.D.J), Emory University School of Medicine, Atlanta, GA.
Abstract
OBJECTIVE: Refrigeration-induced binding of VWF (von Willebrand factor) to platelets contributes to the rapid clearance of refrigerated platelets. In this study, we investigate whether inhibiting VWF binding by a DNA-based aptamer ameliorates the clearance of refrigerated platelets without significantly impeding hemostatic functions. Approach and Results: Platelets were refrigerated with or without aptamer ARC1779 for 48 hours. VWF binding, the effective lifetime of ARC1779, platelet post-transfusion recovery and survival, and the hemostatic function were measured. ARC1779 treatment during refrigeration inhibited the platelet-VWF interaction. ARC1779-treated refrigerated murine platelets exhibited increased post-transfusion recovery and survival than untreated ones (recovery of ARC1779-treated platelets: 76.7±5.5%; untreated: 63.7±0.8%; P<0.01. Half-life: 31.4±2.36 hours versus 28.1±0.86 hours; P<0.05). A similar increase was observed for refrigerated human platelets (recovery: 49.4±4.4% versus 36.8±2.1%, P<0.01; half-life: 9.2±1.5 hours versus 8.7±0.9 hours, ns). The effective lifetime of ARC1779 in mice was 2 hours. Additionally, ARC1779 improved the long-term (2 hours after transfusion) hemostatic function of refrigerated platelets (tail bleeding time of mice transfused with ARC1779-treated refrigerated platelets: 160±65 seconds; untreated: 373±96 seconds; P<0.01). The addition of an ARC1779 antidote before transfusion improved the immediate (15 minutes after transfusion) hemostatic function (bleeding time of treated platelets: 149±21 seconds; untreated: 320±36 seconds; P<0.01). CONCLUSIONS: ARC1779 improves the post-transfusion recovery of refrigerated platelets and preserves the long-term hemostatic function of refrigerated platelets. These results suggest that a short-acting inhibitor of the platelet-VWF interaction may be a potential therapeutic option to improve refrigeration of platelets for transfusion treatment.
OBJECTIVE: Refrigeration-induced binding of VWF (von Willebrand factor) to platelets contributes to the rapid clearance of refrigerated platelets. In this study, we investigate whether inhibiting VWF binding by a DNA-based aptamer ameliorates the clearance of refrigerated platelets without significantly impeding hemostatic functions. Approach and Results: Platelets were refrigerated with or without aptamer ARC1779 for 48 hours. VWF binding, the effective lifetime of ARC1779, platelet post-transfusion recovery and survival, and the hemostatic function were measured. ARC1779 treatment during refrigeration inhibited the platelet-VWF interaction. ARC1779-treated refrigerated murine platelets exhibited increased post-transfusion recovery and survival than untreated ones (recovery of ARC1779-treated platelets: 76.7±5.5%; untreated: 63.7±0.8%; P<0.01. Half-life: 31.4±2.36 hours versus 28.1±0.86 hours; P<0.05). A similar increase was observed for refrigerated human platelets (recovery: 49.4±4.4% versus 36.8±2.1%, P<0.01; half-life: 9.2±1.5 hours versus 8.7±0.9 hours, ns). The effective lifetime of ARC1779 in mice was 2 hours. Additionally, ARC1779 improved the long-term (2 hours after transfusion) hemostatic function of refrigerated platelets (tail bleeding time of mice transfused with ARC1779-treated refrigerated platelets: 160±65 seconds; untreated: 373±96 seconds; P<0.01). The addition of an ARC1779 antidote before transfusion improved the immediate (15 minutes after transfusion) hemostatic function (bleeding time of treated platelets: 149±21 seconds; untreated: 320±36 seconds; P<0.01). CONCLUSIONS: ARC1779 improves the post-transfusion recovery of refrigerated platelets and preserves the long-term hemostatic function of refrigerated platelets. These results suggest that a short-acting inhibitor of the platelet-VWF interaction may be a potential therapeutic option to improve refrigeration of platelets for transfusion treatment.
Entities:
Keywords:
antidote; bleeding time; hemostatics; refrigeration; von Willebrand factor
Authors: James C Gilbert; Tia DeFeo-Fraulini; Renta M Hutabarat; Christopher J Horvath; Patricia G Merlino; H Nicholas Marsh; Judith M Healy; Sleiman Boufakhreddine; Thomas V Holohan; Robert G Schaub Journal: Circulation Date: 2007-11-19 Impact factor: 29.690
Authors: J L Diener; H A Daniel Lagassé; D Duerschmied; Y Merhi; J-F Tanguay; R Hutabarat; J Gilbert; D D Wagner; R Schaub Journal: J Thromb Haemost Date: 2009-04-24 Impact factor: 5.824
Authors: Susan Adam Benard; Thomas M Smith; Kristina Cunningham; Jaison Jacob; Thamara DeSilva; Laura Lin; Gray D Shaw; Ron Kriz; Kerry S Kelleher Journal: Biochemistry Date: 2008-03-26 Impact factor: 3.162
Authors: Florian B Mayr; Paul Knöbl; Bernd Jilma; Jolanta M Siller-Matula; Patricia G Wagner; Robert G Schaub; James C Gilbert; Petra Jilma-Stohlawetz Journal: Transfusion Date: 2010-01-08 Impact factor: 3.157
Authors: Viktoria Rumjantseva; Prabhjit K Grewal; Hans H Wandall; Emma C Josefsson; Anne Louise Sørensen; Göran Larson; Jamey D Marth; John H Hartwig; Karin M Hoffmeister Journal: Nat Med Date: 2009-09-27 Impact factor: 53.440
Authors: Maher M Aljohani; Dana Cialla-May; Jürgen Popp; Raja Chinnappan; Khaled Al-Kattan; Mohammed Zourob Journal: Molecules Date: 2022-01-07 Impact factor: 4.411